MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.340
-0.020
-1.47%
After Hours: 1.340 0 0.00% 16:00 05/16 EDT
OPEN
1.360
PREV CLOSE
1.360
HIGH
1.390
LOW
1.310
VOLUME
31.83K
TURNOVER
0
52 WEEK HIGH
15.86
52 WEEK LOW
1.250
MARKET CAP
31.48M
P/E (TTM)
-0.7400
1D
5D
1M
3M
1Y
5Y
Top Premarket Decliners
MT Newswires · 3d ago
Spruce Biosciences GAAP EPS of -$0.50 misses by $0.06
Spruce Biosciences press release (NASDAQ:SPRB): Q1 GAAP EPS of -$0.50 misses by $0.06. Cash, cash equivalents and investments as of March 31, 2022, were $108.9 million.
Seekingalpha · 5d ago
BRIEF-Spruce Biosciences Reports First Quarter 2022 Results
reuters.com · 5d ago
Spruce Biosciences to Participate in May Investor Conferences
SAN FRANCISCO, May 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that co...
Business Wire · 05/03 20:05
BRIEF-Spruce Biosciences Appoints Libbie Mansell As Chief Regulatory And Quality Officer
reuters.com · 04/11 14:41
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
SAN FRANCISCO, April 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that ...
Business Wire · 04/11 12:00
SPRB, RVMD and LYEL among after hour movers
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp  (TDUP) +7%. Cellectis  (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats  (SEAT) -6%.
Seekingalpha · 04/08 22:02
Where Spruce Biosciences Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade...
Benzinga · 03/16 13:14
More
No Data
Learn about the latest financial forecast of SPRB. Analyze the recent business situations of Spruce Biosciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
42.86%Buy
28.57%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SPRB stock price target is 9.17 with a high estimate of 20.00 and a low estimate of 3.000.
High20.00
Average9.17
Low3.000
Current 1.340
EPS
Actual
Estimate
-0.46-0.34-0.23-0.11
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 51
Institutional Holdings: 19.50M
% Owned: 83.02%
Shares Outstanding: 23.49M
TypeInstitutionsShares
Increased
14
357.91K
New
16
1.68M
Decreased
9
923.30K
Sold Out
10
3.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Chairman/Executive Director
Michael Grey
President/Chief Financial Officer
Samir Gharib
Chief Executive Officer/Director
Javier Szwarcberg
Other
Ralph Charlton
Other
Libbie Mansell
Independent Director
Tiba Aynechi
Independent Director
Dina Chaya
Independent Director
Bali Muralidhar
Independent Director
Niall O'Donnell
Independent Director
Camilla Simpson
Independent Director
Daniel Spiegelman
Independent Director
Kirk Ways
No Data
No Data
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for rare endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. It has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.

Webull offers kinds of Spruce Biosciences Inc stock information, including NASDAQ:SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.